|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/07/24 Anavex Life Sciences Corp. 10-Q 12/31/23 42:2.8M Electro Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 576K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 16K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 16K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
10: R1 Cover HTML 69K
11: R2 Condensed Consolidated Interim Balance Sheets HTML 71K
12: R3 Condensed Consolidated Interim Balance Sheets HTML 28K
(Parenthetical)
13: R4 Condensed Consolidated Interim Statements of HTML 56K
Operations and Comprehensive Loss (Unaudited)
14: R5 Condensed Consolidated Interim Statements of HTML 31K
Operations and Comprehensive Loss (Unaudited)
(Parenthetical)
15: R6 Condensed Consolidated Interim Statements of HTML 43K
Changes in Stockholders' Equity (Unaudited)
16: R7 Condensed Consolidated Interim Statements of Cash HTML 60K
Flows (Unaudited)
17: R8 Business Description HTML 18K
18: R9 Basis of Presentation HTML 31K
19: R10 Other Income HTML 26K
20: R11 Accrued Liabilities HTML 22K
21: R12 Equity Offerings HTML 32K
22: R13 Commitments and Contingencies HTML 125K
23: R14 Basis of Presentation (Policies) HTML 44K
24: R15 Accrued Liabilities (Tables) HTML 21K
25: R16 Commitments and Contingencies (Tables) HTML 117K
26: R17 Basis of Presentation (Details Narrative) HTML 16K
27: R18 Other Income (Details Narrative) HTML 25K
28: R19 Accrued liabilities (Details) HTML 24K
29: R20 Equity Offerings (Details Narrative) HTML 45K
30: R21 Commitments and Contingencies (Details) HTML 16K
31: R22 Commitments and Contingencies (Details 1) HTML 15K
32: R23 Commitments and Contingencies (Details 2) HTML 33K
33: R24 Commitments and Contingencies (Details 3) HTML 56K
34: R25 Commitments and Contingencies (Details 4) HTML 58K
35: R26 Commitments and Contingencies (Details 5) HTML 21K
36: R27 Commitments and Contingencies (Details 6) HTML 23K
37: R28 Commitments and Contingencies (Details Narrative) HTML 55K
39: XML IDEA XML File -- Filing Summary XML 68K
42: XML XBRL Instance -- e5398_10-q_htm XML 519K
38: EXCEL IDEA Workbook of Financial Report Info XLSX 61K
6: EX-101.CAL XBRL Calculations -- avxl-20231231_cal XML 75K
7: EX-101.DEF XBRL Definitions -- avxl-20231231_def XML 191K
8: EX-101.LAB XBRL Labels -- avxl-20231231_lab XML 476K
9: EX-101.PRE XBRL Presentations -- avxl-20231231_pre XML 361K
5: EX-101.SCH XBRL Schema -- avxl-20231231 XSD 77K
40: JSON XBRL Instance as JSON Data -- MetaLinks 219± 311K
41: ZIP XBRL Zipped Folder -- 0001731122-24-000206-xbrl Zip 213K
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Anavex Life Sciences Corp. (the “Company”) on Form 10-Q for the three months ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: February 7, 2024 | /s/Christopher Missling, PhD |
| Christopher Missling, PhD | |
| Chief Executive Officer, President, Secretary | |
| (Principal Executive Officer) |
| /s/Sandra Boenisch | |
| Sandra Boenisch, CPA, CGA | |
| Principal Financial Officer, Treasurer | |
| (Principal Financial and Accounting Officer) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/7/24 | None on these Dates | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/24/21 Anavex Life Sciences Corp. 10-K 9/30/21 50:13M Electro Filings LLC/FA |